Repositioning Candidate Details
| Candidate ID: | R0562 |
| Source ID: | DB02383 |
| Source Type: | withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Tolrestat |
| Synonyms: | Tolrestat |
| Molecular Formula: | C16H14F3NO3S |
| SMILES: | COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F |
| Structure: |
|
| DrugBank Description: | Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. |
| CAS Number: | 82964-04-3 |
| Molecular Weight: | 357.347 |
| DrugBank Indication: | For the pharmacological control of certain diabetic complications. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Aldose reductase inhibitor; Alcohol dehydrogenase [NADP(+)]; Aldo-keto reductase family 1 member B10 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|